Forest Riekhof et al. Clin Genitourin Cancer. 2023.
Abstract
Background: Abiraterone and enzalutamide are second generation androgen receptor pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without head-to-head comparative studies identifying 1 agent as preferred initial therapy, physician preferences guide initial ARPI choice. This study compares hospitalizations among patients treated initially with abiraterone versus enzalutamide.
Total rate of hospitalization increased 22% for abiraterone compared to a 3% increase for enzalutamide in the 12 months after ARPI initiation (P < .0001). Abiraterone was associated with greater increase in rates of acute heart failure, atrial fibrillation, acute kidney injury, urinary tract infections, sepsis, and pneumonia.
Interesting article . Yes Im a Veteran being treated at Hines V.A. hospital in Illinois . Im 18 months on Eligard , Zytiga ( abi ) and prednisone and starting to notice heart issues . So I might have the talk to my V.A. MO. Thanks , SemperFi , JJ
thank you for sharing this extremely important information. Not a placebo controlled randomized trial but the effect size snd sample size are certainly large enough yo looks closely for any moderator variables that might account for the difference
I've been on Abiraterone for almost 3 years. I may want to try enzalutamide when abiraterone stops working. If I do my out of pocket expenses will go up by thousands of dollars per year. I will keep a close I on my heart, kidney and liver function, but continue my current course.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.